These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 18673245)

  • 1. Wnt signaling in renal cancer.
    Guillén-Ahlers H
    Curr Drug Targets; 2008 Jul; 9(7):591-600. PubMed ID: 18673245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wnt signaling and cancer development: therapeutic implication.
    Paul S; Dey A
    Neoplasma; 2008; 55(3):165-76. PubMed ID: 18348648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNAs Associated with Von Hippel-Lindau Pathway in Renal Cell Carcinoma: A Comprehensive Review.
    Schanza LM; Seles M; Stotz M; Fosselteder J; Hutterer GC; Pichler M; Stiegelbauer V
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29165391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the Wnt/β-catenin signaling pathway in human cancers.
    Yao H; Ashihara E; Maekawa T
    Expert Opin Ther Targets; 2011 Jul; 15(7):873-87. PubMed ID: 21486121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the most upstream site of Wnt signaling pathway provides a strategic advantage for therapy in colorectal cancer.
    Qi J; Zhu YQ
    Curr Drug Targets; 2008 Jul; 9(7):548-57. PubMed ID: 18673240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IGFBP-4 activates the Wnt/beta-catenin signaling pathway and induces M-CAM expression in human renal cell carcinoma.
    Ueno K; Hirata H; Majid S; Tabatabai ZL; Hinoda Y; Dahiya R
    Int J Cancer; 2011 Nov; 129(10):2360-9. PubMed ID: 21207373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Wnt/Frizzled signaling in hepatocellular carcinoma.
    Lee HC; Kim M; Wands JR
    Front Biosci; 2006 May; 11():1901-15. PubMed ID: 16368566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic potential of targeting the Wnt/β-catenin signaling pathway in colorectal cancer.
    Cheng X; Xu X; Chen D; Zhao F; Wang W
    Biomed Pharmacother; 2019 Feb; 110():473-481. PubMed ID: 30530050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wnt signaling as a therapeutic target for cancer.
    Herbst A; Kolligs FT
    Methods Mol Biol; 2007; 361():63-91. PubMed ID: 17172707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The β-catenin/TCF complex as a novel target of resveratrol in the Wnt/β-catenin signaling pathway.
    Chen HJ; Hsu LS; Shia YT; Lin MW; Lin CM
    Biochem Pharmacol; 2012 Nov; 84(9):1143-53. PubMed ID: 22935447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway.
    Urakami S; Shiina H; Enokida H; Kawakami T; Tokizane T; Ogishima T; Tanaka Y; Li LC; Ribeiro-Filho LA; Terashima M; Kikuno N; Adachi H; Yoneda T; Kishi H; Shigeno K; Konety BR; Igawa M; Dahiya R
    Clin Cancer Res; 2006 Jan; 12(2):383-91. PubMed ID: 16428476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The emerging role of nuclear factor kappa B in renal cell carcinoma.
    Morais C; Gobe G; Johnson DW; Healy H
    Int J Biochem Cell Biol; 2011 Nov; 43(11):1537-49. PubMed ID: 21854869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Wnt/beta-catenin/tcf signaling: a critical pathway in gastrointestinal tumorigenesis.
    Kolligs FT; Bommer G; Göke B
    Digestion; 2002; 66(3):131-44. PubMed ID: 12481159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of the VHL, HIF-1α, and VEGF Signaling Pathway and Associated MAPK (ERK1/2 and ERK5) Pathways in Clear-Cell Renal Cell Carcinoma. A Long-Term Study.
    Salinas-Sánchez AS; Serrano-Oviedo L; Nam-Cha SY; Roche-Losada O; Sánchez-Prieto R; Giménez-Bachs JM
    Clin Genitourin Cancer; 2017 Dec; 15(6):e923-e933. PubMed ID: 28624320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An oncogenic hub: beta-catenin as a molecular target for cancer therapeutics.
    Takemaru KI; Ohmitsu M; Li FQ
    Handb Exp Pharmacol; 2008; (186):261-84. PubMed ID: 18491056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VHL missense mutations in the p53 binding domain show different effects on p53 signaling and HIFα degradation in clear cell renal cell carcinoma.
    Razafinjatovo CF; Stiehl D; Deininger E; Rechsteiner M; Moch H; Schraml P
    Oncotarget; 2017 Feb; 8(6):10199-10212. PubMed ID: 28052007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic targets in the Wnt signaling pathway: Feasibility of targeting TNIK in colorectal cancer.
    Masuda M; Sawa M; Yamada T
    Pharmacol Ther; 2015 Dec; 156():1-9. PubMed ID: 26542362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Dual-role regulations of canonical Wnt/beta-catenin signaling pathway].
    Liu Y; Zhang CG; Zhou CY
    Beijing Da Xue Xue Bao Yi Xue Ban; 2010 Apr; 42(2):238-42. PubMed ID: 20396373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New avenues to target Wnt/β-catenin signaling.
    Verkaar F; Zaman GJ
    Drug Discov Today; 2011 Jan; 16(1-2):35-41. PubMed ID: 21111060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal carcinogenesis--insights into signaling pathways.
    Cojocaru E; Lozneanu L; Giuşcă SE; Căruntu ID; Danciu M
    Rom J Morphol Embryol; 2015; 56(1):15-9. PubMed ID: 25826482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.